SCHEMBL6100619

SCHEMBL6100619

CC[C@]1(COC(=O)c2ccccc2)O[C@H](OC)[C@H](O)[C@@H]1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.39
▸ TDP1 Q9NUW8 3/20 0.38
▸ TSHR P16473 2/20 0.38
▸ SLC6A3 Q01959 2/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ HIF1A Q16665 1/20 0.37
▸ SLC6A2 P23975 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ SLC22A1 O15245 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ ADRB2 P07550 2/20 0.36
▸ ADRB1 P08588 2/20 0.36
▸ ADRB3 P13945 2/20 0.36
▸ GAA P10253 1/20 0.36
▸ SYNJ2 O15056 3/20 0.36
▸ HTR1A P08908 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6100614 1.00 LMNA (0.42) LMNAALDH1A1TDP1TSHRSLC6A3
SCHEMBL6099706 0.94 LMNA (0.42) LMNAALDH1A1TDP1TSHRSLC6A3
SCHEMBL6099711 0.94 LMNA (0.42) LMNAALDH1A1TDP1TSHRSLC6A3
SCHEMBL5553679 0.81 MAPT (0.40) LMNAALDH1A1TDP1TSHR
SCHEMBL5553671 0.81 MAPT (0.40) LMNAALDH1A1TDP1TSHR
SCHEMBL14615904 0.81 MAPT (0.40) LMNAALDH1A1TDP1TSHR
SCHEMBL6099509 0.77 MAPT (0.42) LMNAALDH1A1TDP1TSHRSLC6A3
SCHEMBL6099512 0.77 MAPT (0.42) LMNAALDH1A1TDP1TSHRSLC6A3
SCHEMBL7214561 0.76 ALDH1A1 (0.39) LMNAALDH1A1TDP1TSHRSLC6A3
SCHEMBL16063068 0.76 ABCB1 (0.41) LMNAALDH1A1SLC22A1GAASYNJ2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7081449-B2 Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides VALEANT RESEARCH & DEVELOPMENT (US) 2006-07-25 — — US disclosed
EP-1303282-A4 PYRIDO[2,3-D]PYRIMIDINE AND PYRIMIDO[4,5-D]PYRIMIDINE NUCLEOSIDES RIBAPHARM INC (US) 2004-04-07 — — EP disclosed
US-20030144502-A1 Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides MDRNA RESEARCH, INC. 2003-07-31 — — US disclosed
EP-1303282-A1 PYRIDO[2,3-D]PYRIMIDINE AND PYRIMIDO[4,5-D]PYRIMIDINE NUCLEOSIDES Ribapharm, Inc. (US) 2003-04-23 — — EP disclosed
WO-2002003997-A1 PYRIDO[2,3-D]PYRIMIDINE AND PYRIMIDO[4,5-D]PYRIMIDINE NUCLEOSIDES RIBAPHARM INC. (US) 2002-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144502-A1 Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides DPYD, TYMP, PNPO LMNA 2724/4885ALDH1A1 1759/4885TDP1 812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback